Related Experiment Video
Updated: May 28, 2026
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
[SOCS3: a potential therapeutic target for many human diseases]
1Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|October 21, 2011
Summary
Suppressor of Cytokine Signaling 3 (SOCS3) plays a key role in cell signaling and human diseases. Its levels and function are crucial for diagnosing and treating conditions like inflammation, obesity, and cancer.
Area of Science:
- Molecular Biology
- Immunology
- Pathology
Background:
- Suppressor of Cytokine Signaling 3 (SOCS3) is a critical regulator of cytokine signaling pathways.
- SOCS3 is induced by various cytokines and pro-inflammatory factors, influencing physiological functions and tissue pathology.
Purpose of the Study:
- To review the multifaceted role of SOCS3 in the pathogenesis, diagnosis, and treatment of human diseases.
- To highlight SOCS3's potential as a diagnostic biomarker and therapeutic target.
Main Methods:
- Literature review of studies on SOCS3.
- Analysis of SOCS3's involvement in inflammation, viral infections, obesity, and cancer.
- Evaluation of SOCS3's diagnostic and prognostic value.
Main Results:
- Abnormal SOCS3 levels or function are linked to disease onset and progression.
- SOCS3 influences key cellular signaling pathways relevant to disease.
- Evidence supports SOCS3's role in inflammation, viral infections, obesity, and tumorigenesis.
Conclusions:
- SOCS3 is a significant factor in the development and progression of various human diseases.
- SOCS3 serves as a potential biomarker for disease diagnosis and prognosis.
- Targeting SOCS3 offers a promising therapeutic strategy for multiple disorders.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...